Stoking the flames.
Osimertinib is the preferred first-line or maintenance therapy for patients with advanced, EGFR-mutated non-small cell lung cancer (NSCLC). Because consolidative or palliative chest radiation may be used at some point, what’s the risk of radiation pneumonitis with concurrent chest radiation and osimertinib? This small (n=11) retrospective study suggests caution. Nearly two-thirds of patients treated with chest radiation concurrent with osimertinib developed at least grade 2 pneumonitis (requiring medication) and nearly half had grade 3 pneumonitis (requiring oxygen). TBL: A high rate of pneumonitis should be weighed against potential benefits of adding thoracic radiation in the setting of osimertinib. | Jia, Radiother Oncol 2020